The stock has a 36-month beta value of 1.27. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CTKB is 114.61M, and at present, short sellers hold a 4.72% of that float. On June 20, 2025, the average trading volume of CTKB was 1.10M shares.
CTKB) stock’s latest price update
The stock of Cytek BioSciences Inc (NASDAQ: CTKB) has decreased by -3.76 when compared to last closing price of 3.19. Despite this, the company has experienced a -10.76% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that Cytek has announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system.
CTKB’s Market Performance
Cytek BioSciences Inc (CTKB) has seen a -10.76% fall in stock performance for the week, with a 14.13% gain in the past month and a -27.25% plunge in the past quarter. The volatility ratio for the week is 3.16%, and the volatility levels for the past 30 days are at 5.39% for CTKB. The simple moving average for the last 20 days is 1.93% for CTKB stock, with a simple moving average of -37.76% for the last 200 days.
Analysts’ Opinion of CTKB
Many brokerage firms have already submitted their reports for CTKB stocks, with TD Cowen repeating the rating for CTKB by listing it as a “Hold.” The predicted price for CTKB in the upcoming period, according to TD Cowen is $4 based on the research report published on May 09, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see CTKB reach a price target of $4.50, previously predicting the price at $7. The rating they have provided for CTKB stocks is “Sell” according to the report published on January 31st, 2025.
Stephens gave a rating of “Overweight” to CTKB, setting the target price at $9 in the report published on December 14th of the previous year.
CTKB Trading at -6.66% from the 50-Day Moving Average
After a stumble in the market that brought CTKB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.76% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTKB starting from McCombe William D., who purchase 35,000 shares at the price of $2.78 back on Jun 02 ’25. After this action, McCombe William D. now owns 55,746 shares of Cytek BioSciences Inc, valued at $97,300 using the latest closing price.
Stock Fundamentals for CTKB
Current profitability levels for the company are sitting at:
- -0.13 for the present operating margin
- 0.55 for the gross margin
The net margin for Cytek BioSciences Inc stands at -0.06. The total capital return value is set at -0.06. Equity return is now at value -2.91, with -2.31 for asset returns.
Based on Cytek BioSciences Inc (CTKB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 2.86. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 651.68.
Currently, EBITDA for the company is -10.03 million with net debt to EBITDA at 9.4. When we switch over and look at the enterprise to sales, we see a ratio of 1.53. The receivables turnover for the company is 3.58for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.62.
Conclusion
To sum up, Cytek BioSciences Inc (CTKB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
